Clinical Value of Loss of Heterozygosity in Serum Microsatellite DNA of Patients With Gastrointestinal Stromal Tumors.
Standard
Clinical Value of Loss of Heterozygosity in Serum Microsatellite DNA of Patients With Gastrointestinal Stromal Tumors. / Schurr, Paulus; Oikonomou, Despina; Kaifi, Jussuf; Merkert, Petra; Wolter, Stephan; Kleinhans, Helge; Reichelt, Uta; Mann, Oliver; Gawad, Karim A.; Strate, Tim; Yekebas, Emre F.; Izbicki, Jakob R.
in: J CLIN GASTROENTEROL, Jahrgang 43, Nr. 1, 1, 2009, S. 27-35.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical Value of Loss of Heterozygosity in Serum Microsatellite DNA of Patients With Gastrointestinal Stromal Tumors.
AU - Schurr, Paulus
AU - Oikonomou, Despina
AU - Kaifi, Jussuf
AU - Merkert, Petra
AU - Wolter, Stephan
AU - Kleinhans, Helge
AU - Reichelt, Uta
AU - Mann, Oliver
AU - Gawad, Karim A.
AU - Strate, Tim
AU - Yekebas, Emre F.
AU - Izbicki, Jakob R.
PY - 2009
Y1 - 2009
N2 - GOALS: To study the role of loss of heterozygosity (LOH) in serum microsatellite DNA of patients with gastrointestinal stromal tumors (GIST). BACKGROUND: In GIST, tumor markers from peripheral blood are missing. STUDY: Seventy-eight patients (59 GIST, 13 leiomyomas, 2 leiomyosarcomas, and 4 schwannomas) underwent resection at our institute between 1985 and 2006. Thirty-three preoperative sera (26 GIST and 7 non-GIST) and 62 postoperative sera (47 GIST and 15 non-GIST) were available and tested for alterations in 12 representative microsatellite loci on chromosomes 22, 17, 13, 9, and 3, using fluorescence-based automated capillary electrophoresis by ABI Prism. Survival was calculated with Kaplan-Meier plots. RESULTS: Seventeen out of 26 GIST patients had a positive preoperative serum LOH score (>/=2 LOH, sensitivity 65.4%), and 6 out of 7 non-GIST patients had a negative score (/=2 LOH preoperatively. Postoperative sensitivity and specificity of LOH analysis for prediction of relapse in 47 GIST was 75.0% and 64.1%, respectively. After a median observation time of 51.3 months (95% confidence interval, 39.4-61.4), LOH in serum significantly predicted overall survival (P=0.007, log-rank test). CONCLUSIONS: LOH serum analysis in GIST may play a role as a noninvasive, differential diagnostic, prognostic, and monitoring marker in the clinical routine.
AB - GOALS: To study the role of loss of heterozygosity (LOH) in serum microsatellite DNA of patients with gastrointestinal stromal tumors (GIST). BACKGROUND: In GIST, tumor markers from peripheral blood are missing. STUDY: Seventy-eight patients (59 GIST, 13 leiomyomas, 2 leiomyosarcomas, and 4 schwannomas) underwent resection at our institute between 1985 and 2006. Thirty-three preoperative sera (26 GIST and 7 non-GIST) and 62 postoperative sera (47 GIST and 15 non-GIST) were available and tested for alterations in 12 representative microsatellite loci on chromosomes 22, 17, 13, 9, and 3, using fluorescence-based automated capillary electrophoresis by ABI Prism. Survival was calculated with Kaplan-Meier plots. RESULTS: Seventeen out of 26 GIST patients had a positive preoperative serum LOH score (>/=2 LOH, sensitivity 65.4%), and 6 out of 7 non-GIST patients had a negative score (/=2 LOH preoperatively. Postoperative sensitivity and specificity of LOH analysis for prediction of relapse in 47 GIST was 75.0% and 64.1%, respectively. After a median observation time of 51.3 months (95% confidence interval, 39.4-61.4), LOH in serum significantly predicted overall survival (P=0.007, log-rank test). CONCLUSIONS: LOH serum analysis in GIST may play a role as a noninvasive, differential diagnostic, prognostic, and monitoring marker in the clinical routine.
M3 - SCORING: Zeitschriftenaufsatz
VL - 43
SP - 27
EP - 35
JO - J CLIN GASTROENTEROL
JF - J CLIN GASTROENTEROL
SN - 0192-0790
IS - 1
M1 - 1
ER -
